Adenoviral Vector Development Platform
Adenoviral (AdV) vectors are currently one of the most widely used gene therapy viral vectors. Compared to other viral vectors, adenoviruses have advantages such as high gene transduction efficiency, broad tissue tropism, and not integrating into the host genome. As a company with extensive experience in the field of gene therapy, our company is dedicated to providing adenoviral vector development services to accelerate the development of effective gene therapies for rare diseases.
Introduction to Adenoviral Vectors
Adenovirus is a large molecule (36 kb), non-enveloped, double-stranded DNA virus. It enters cells through receptor-mediated endocytosis and then transfers its genome to the cell nucleus, where it remains outside the chromosomes without integrating into the host cell genome.
Adenoviral (AdV) vectors can be recombined to form adenoviruses. Adenoviral vectors play a crucial role in gene delivery in the therapeutics of rare diseases and gene therapy. Several experiments have demonstrated that the use of adenoviral vectors allows for gene delivery and expression, providing an effective pathway for the therapeutics of rare diseases.
Fig.1 Adenovirus structure organization and interaction with host cell. (Mendonça, S. A., et al., 2021)
Advantages of Adenoviral Vectors
- The development of non-replicating adenoviral vectors has allowed us to circumvent immune responses against adenoviral vectors.
- The majority of human cells express the primary adenoviral receptor and a secondary integrin receptor so they are easily infected by adenoviral vectors, leading to high levels of transgene expression.
- In many applications related to adenoviruses, safe dosages and administration routes have now been established.
- Adenoviral vectors provide a universal platform for developing strategies to modify the viral capsid, enhancing the therapeutic properties and specificity of the virus.
Adenoviral Vectors for Rare Diseases
With the increase of time and experience and the progress of molecular biology techniques, the use of adenovirus vectors has become more effective. The third-generation adenovirus vector, called high-capacity adenoviral vector (HC-AdV), has become the most promising adenovirus vector for gene therapy. At present, gene therapy based on adenovirus vector has been used to develop therapies for many rare diseases, such as malignant simple mesothelioma (MPM), naive diffuse intrinsic point gliomas, and malignant melanoma.
Our Services
Focused on cutting-edge technologies in the field of molecular biology and cell biology for many years, our company is committed to providing customers with adenovirus vectors development and vector evaluation services to produce milder immune responses to deliver larger DNA packages with less risk, accelerating the development of effective gene therapies for rare diseases. Our services include, but are not limited to:
- AdV Molecular Design
The AdV molecular design services we can provide include but are not limited to:
- AdV complementation system design
- AdV capsid selection and optimization
- Target gene integration
- Sequencing
- AdV Production
Transfection and high titer virus production services are optional. In addition, we can provide efficient production of recombinant AdV vectors, including:
- Generation of AdV vector by Cre-lox site-specific recombination system.
- Generation of recombinant AdV vectors by simplified and user-friendly AdEasy system.
- Generation of recombinant helper-dependent (HD) AdV by helper plasmid-based system.
- AdV Purification
Providing AdV purification services through the combination of chromatography approaches based on capture antibodies, ion exchange, hydrophobic interaction, size exclusion, and immobilized metal affinity columns according to your needs and plans.
Why Choose Us?
With extensive experience in rare disease therapy research and development, our company provides customers with a convenient solution. Our adenoviral vector development service is a simplified workflow by a group of specially trained and professional scientists. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Mendonça, S. A., et al. "Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic." npj Vaccines 6.1 (2021): 97.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.